Cardio Diagnostics Holdings (CDIO) Stock Overview
Develops and commercializes epigenetics-based clinical tests for cardiovascular disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
CDIO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Cardio Diagnostics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.04 |
| 52 Week High | US$17.39 |
| 52 Week Low | US$0.97 |
| Beta | 2.23 |
| 1 Month Change | -60.77% |
| 3 Month Change | -24.72% |
| 1 Year Change | -80.28% |
| 3 Year Change | -97.65% |
| 5 Year Change | n/a |
| Change since IPO | -99.31% |
Recent News & Updates
Shareholder Returns
| CDIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.4% | 2.3% | -0.3% |
| 1Y | -80.3% | 31.7% | 16.1% |
Return vs Industry: CDIO underperformed the US Biotechs industry which returned 31.7% over the past year.
Return vs Market: CDIO underperformed the US Market which returned 16% over the past year.
Price Volatility
| CDIO volatility | |
|---|---|
| CDIO Average Weekly Movement | 36.6% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: CDIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CDIO's weekly volatility has increased from 23% to 37% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 16 | Meesha Dogan | cdio.ai |
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform.
Cardio Diagnostics Holdings, Inc. Fundamentals Summary
| CDIO fundamental statistics | |
|---|---|
| Market cap | US$5.77m |
| Earnings (TTM) | -US$6.50m |
| Revenue (TTM) | US$14.83k |
Is CDIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDIO income statement (TTM) | |
|---|---|
| Revenue | US$14.83k |
| Cost of Revenue | US$0 |
| Gross Profit | US$14.83k |
| Other Expenses | US$6.51m |
| Earnings | -US$6.50m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.20 |
| Gross Margin | 100.00% |
| Net Profit Margin | -43,832.49% |
| Debt/Equity Ratio | 3.9% |
How did CDIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 06:32 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cardio Diagnostics Holdings, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Carl Byrnes | Northland Capital Markets |